Treatment for hepatocellular carcinoma in elderly patients: A literature review

Journal of Cancer

Volumn 4, Issue 8, 2013, Pages 635-643

  Nishikawa, Hiroki ^a   Kimura, Toru ^a   Kita, Ryuichi ^a   Osaki, Yukio ^a  

^a OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

Cancer treatment; Clinical characteristics; Clinical outcome; Elderly patients; Hepatocellular carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; SORAFENIB;

ADVANCED CANCER; AGING; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMORBIDITY; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG TOLERABILITY; ELDERLY CARE; GERIATRIC DISORDER; HEPATITIS B; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; LIVING DONOR; MOLECULARLY TARGETED THERAPY; MORBIDITY; MULTIMODALITY CANCER THERAPY; PATIENT SAFETY; PERCUTANEOUS RADIOFREQUENCY ABLATION; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84885439523     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.7279     Document Type: Review

References (106)

1. Kudo M. Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology 2010; 78: 113-24.
2. Livraghi T, Mäkisalo H, Line PD. Treatment options in hepatocellular carcinoma today. Scand J Surg 2011; 100: 22-9.
3. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-73.
4. de Lope CR, Tremosini S, Forner A, et al. Management of HCC. J Hepatol 2012; 56 Suppl 1: S75-S87.
5. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365(12): 1118-27.
6. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology. 2010; 53(1): 39-43.
7. Hankey BF, Ries LA, Kosary CL, et al. Partitioning linear trends in age-adjusted rates. Cancer Causes Control 2000; 11: 31-35.
8. [Internet] Ministry of Health. Labour and Welfare. Abridged life tables for Japan 2006. http://www.mhlw.go.jp/english/database/db-hw/lifetb06/index.html.
9. Cho SJ, Yoon JH, Hwang SS, et al. Do young hepatocellular carcinoma patients with relatively good liver function have poorer outcomes than elderly patients? J Gastroenterol Hepatol 2007; 22: 1226-1231.
10. Asahina Y, Tsuchiya K, Tamaki N, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010; 52: 518-527.
11. Kiyosawa K, Tanaka E. Characteristics of hepatocellular carcinoma in Japan. Oncology 2002; 62 Suppl 1: 5-7.
12. Ikai I, Arii S, Okazaki M, et al: The Liver Cancer Study Group of Japan, Kyoto, Japan. Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 2007; 37: 676-691.
13. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010; 42 Suppl 3: S206-S214.
14. Cohen MJ, Bloom AI, Barak O, et al. Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma. World J Gastroenterol. 2013; 19(16): 2521-8.
15. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362(9399): 1907-17.
16. Rahbari NN, Mehrabi A, Mollberg NM, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 2011; 253(3): 453-69.
17. Tanaka J, Kumagai J, Katayama K, et al. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. Intervirology. 2004; 47(1): 32-40.
18. Wyles DL. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis. 2013; 207 Suppl 1: S33-9.
19. Cobb B, Pockros PJ, Vilchez RA, et al. HCV RNA viral load assessments in the era of direct-acting antivirals. Am J Gastroenterol. 2013; 108(4): 471-5.
20. Asselah T, Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver Int. 2013; 33 Suppl 1: 93-104.
21. Nishikawa H, Osaki Y, Iguchi E, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma: clinical outcome and safety in elderly patients. J Gastrointestin Liver Dis 2012; 21(4): 397-405.
22. Takahashi H, Mizuta T, Kawazoe S, et al. Efficacy and safety of radiofrequency ablation for elderly hepatocellular carcinoma patients. Hepatol Res. 2010; 40(10): 997-1005.
23. Kao WY, Chiou YY, Hung HH, et al. Younger hepatocellular carcinoma patients have better prognosis after percutaneous radiofrequency ablation therapy. J Clin Gastroenterol. 2012; 46(1): 62-70.
24. Kondo K, Chijiiwa K, Funagayama M, et al. Hepatic resection is justified for elderly patients with hepatocellular carcinoma. World J Surg. 2008; 32(10): 2223-9.
25. Huang J, Li BK, Chen GH, et al. Long-term outcomes and prognostic factors of elderly patients with hepatocellular carcinoma undergoing hepatectomy. J Gastrointest Surg. 2009; 13(9): 1627-35.
26. Su CW, Lei HJ, Chau GY, et al. The effect of age on the long-term prognosis of patients with hepatocellular carcinoma after resection surgery: a propensity score matching analysis. Arch Surg. 2012; 147(2): 137-44 27.
27. Poon RT, Fan ST, Lo CM, et al. Hepatocellular carcinoma in the elderly: results of surgical and nonsurgical management. Am J Gastroenterol. 1999; 94(9): 2460-6.
28. Yeh CN, Lee WC, Jeng LB, et al. Hepatic resection for hepatocellular carcinoma in elderly patients. Hepatogastroenterology. 2004; 51(55): 219-23.
29. Nishikawa H, Arimoto A, Wakasa T, et al. Surgical resection for hepatocellular carcinoma: clinical outcomes and safety in elderly patients. Eur J Gastroenterol Hepatol. 2013; [Epub ahead of print]
30. Zhou L, Rui JA, Wang SB, et al. Clinicopathological features, post-surgical survival and prognostic indicators of elderly patients with hepatocellular carcinoma. Eur J Surg Oncol. 2006; 32(7): 767-72.
31. Reddy SK, Barbas AS, Turley RS, et al. Major liver resection in elderly patients: a multi-institutional analysis. J Am Coll Surg. 2011; 212(5): 787-95.
32. Mirici-Cappa F, Gramenzi A, Santi V, et al; Italian Liver Cancer Group. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. Gut. 2010; 59(3): 387-96.
33. Takenaka K, Shimada M, Higashi H, et al. Liver resection for hepatocellular carcinoma in the elderly. Arch Surg. 1994; 129(8): 846-50.
34. Tsujita E, Utsunomiya T, Ohta M, et al. Outcome of repeat hepatectomy in patients with hepatocellular carcinoma aged 75 years and older. Surgery. 2010; 147(5): 696-703.
35. Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest. 2000; 117: 1239-1246.
36. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334(11): 693-9.
37. Zhou WP, Lai EC, Li AJ, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg 2009; 249(2): 195-202.
38. Nishikawa H, Arimoto A, Wakasa T, et al. Effect of transcatheter arterial chemoembolization prior to surgical resection for hepatocellular carcinoma. Int J Oncol 2013; 42(1): 151-60.
39. Nishikawa H, Osaki Y, Iguchi E, et al. Percutaneous radiofrequency ablation therapy for recurrent hepatocellular carcinoma. Anticancer Res 2012; 32(11): 5059-65.
40. Nishikawa H, Osaki Y, Kita R, et al. Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence. Int J Oncol 2012; 41(3): 903-9.
41. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56(4): 908-43.
42. Kudo M, Izumi N, Kokudo N, et al; HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: Consensus- Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29(3): 339-64.
43. Honda T, Miyaaki H, Ichikawa T, et al. Clinical characteristics of hepatocellular carcinoma in elderly patients. Oncol Lett. 2011; 2(5): 851-854.
44. Yau T, Yao TJ, Chan P, et al. The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization. Cancer. 2009; 115(23): 5507-15.
45. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132(7): 2557-76.
46. Miki D, Aikata H, Uka K, et al. Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol. 2008; 43(7): 550-7.
47. Oishi K, Itamoto T, Kobayashi T, et al. Hepatectomy for hepatocellular carcinoma in elderly patients aged 75 years or more. J Gastrointest Surg. 2009; 13(4): 695-701.
48. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010; 51(6): 1972-8.
49. Yasui K, Hashimoto E, Tokushige K, et al; The Japan NASH Study Group. Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. Hepatol Res. 2012; 42(8): 767-773.
50. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003; 37(5): 1202-19.
51. Isokawa O, Suda T, Aoyagi Y, et al. Reduction of telomeric repeats as a possible predictor for development of hepatocellular carcinoma: convenient evaluation by slot-blot analysis. Hepatology. 1999; 30(2): 408-12.
52. Ahuja N, Li Q, Mohan AL, et al. Aging and DNA methylation in colorectal mucosa and cancer. Hepatol Res. 2012; 42(8): 767-773.
53. Cescon M, Grazi GL, Del Gaudio M, et al. Outcome of right hepatectomies in patients older than 70 years. Arch Surg. 2003; 138(5): 547-52.
54. Shirabe K, Kajiyama K, Harimoto N, et al. Early outcome following hepatic resection in patients older than 80 years of age. World J Surg. 2009; 33(9): 1927-32.
55. Kaibori M, Matsui K, Ishizaki M, et al. Hepatic resection for hepatocellular carcinoma in the elderly. J Surg Oncol. 2009; 99(3): 154-60.
56. Nishikawa H, Osaki Y, Iguchi E, et al. The effect of long-term supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation. J Clin Gastroenterol. 2013; 47(4): 359-66.
57. Mazzaferro V, Romito R, Schiavo M, et al; HCC Italian Task Force. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006; 44(6): 1543-54.
58. Makuuchi M, Sano K. The surgical approach to HCC: our progress and results in Japan. Liver Transpl 2004; 10(2 Suppl 1): S46-52.
59. Ishizawa T, Mise Y, Aoki T, et al. Surgical technique: new advances for expanding indications and increasing safety in liver resection for HCC: the Eastern perspective. J Hepatobiliary Pancreat Sci. 2010; 17(4): 389-93.
60. Toso C, Cader S, Mentha-Dugerdil A, et al. Factors predicting survival after post-transplant hepatocellular carcinoma recurrence. J Hepatobiliary Pancreat Sci. 2013; 20(3): 342-7.
61. Sato M, Tateishi R, Yasunaga H, et al. Mortality and morbidity of hepatectomy, radiofrequency ablation, and embolization for hepatocellular carcinoma: a national survey of 54,145 patients. J Gastroenterol. 2012; 47(10): 1125-33.
62. Portolani N, Baiocchi GL, Coniglio A, et al. Limited liver resection: a good indication for the treatment of hepatocellular carcinoma in elderly patients. Jpn J Clin Oncol. 2011; 41(12): 1358-65.
63. Forner A, Reig ME, de Lope CR, et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30(1): 61-74.
64. Clavien PA, Lesurtel M, Bossuyt PM, et al; OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13(1): e11-22.
65. Tsochatzis EA, Bosch J, Burroughs AK. New therapeutic paradigm for patients with cirrhosis. Hepatology 2012; 56(5): 1983-92.
66. Sugawara Y, Makuuchi M. Living donor liver transplantation: present status and recent advances. Br Med Bull 2006; 75-76: 15-28.
67. Sugawara Y, Makuuchi M. Advances in adult living donor liver transplantation: a review based on reports from the 10th anniversary of the adult-to-adult living donor liver transplantation meeting in Tokyo. Liver Transpl 2004; 10(6): 715-20.
68. Taner CB, Ung RL, Rosser BG, et al. Age is not a contraindication for orthotopic liver transplantation: a single institution experience with recipients older than 75 years. Hepatology International. 2011; In press.
69. Thuluvath PJ, Guidinger MK, Fung JJ, et al. Liver transplantation in the United States, 1999-2008. Am J Transplant. 2010; 10: 1003-1019.
70. Selzner M, KashfiA, Selzner N, et al. Recipient age affects long-term outcome and hepatitis C recurrence in old donor livers following transplantation. Liver Transpl. 2009; 15(10): 1288-95.
71. Randall HB, Cao S, deVera ME. Transplantation in elderly patients. Arch Surg. 2003; 138(10): 1089-92.
72. Zetterman RK, Belle SH, Hoofnagle JH, et al. Age and liver transplantation: a report of the Liver Transplantation Database. Transplantation. 1998; 66(4): 500-6.
73. Lencioni R, Crocetti L. Image-guided ablation for hepatocellular carcinoma. Recent Results Cancer Res. 2013; 190: 181-94.
74. Nishikawa H, Osaki Y, Iguchi E, et al. Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes. J Gastroenterol 2012; Epub ahead of print.
75. Nishikawa H, Inuzuka T, Takeda H, et al. Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation. J Gastroenterol 2011; 46(12): 1418-26.
76. Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012; 107(4): 569-77.
77. Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005; 103(6): 1201-9.
78. Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg 2011; 98(9): 1210-24.
79. Morimoto M, Numata K, Kondou M, et al. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 2010; 116(23): 5452-60.
80. Fujii H, Itoh Y, Ohnishi N, et al. Factors associated with the overall survival of elderly patients with hepatocellular carcinoma. World J Gastroenterol 2012; 18: 1926-1932
81. Lencioni R. Chemoembolization for hepatocellular carcinoma. Semin Oncol. 2012; 39(4): 503-9.
82. Takayasu K, Arii S, Ikai I, et al; Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-9.
83. Matsui O. Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization. Clin Drug Investig 2012; 32 Suppl 2:3-13.
84. Matsui O, Miyayama S, Sanada J, et al. Interventional oncology: new options for interstitial treatments and intravascular approaches: superselective TACE using iodized oil for HCC: rationale, technique and outcome. J Hepatobiliary Pancreat Sci 2010; 17(4): 407-9.
85. Yamada R, Sato M, Kawabata M, et al. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148(2): 397-401.
86. Takayasu K. Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective. Jpn J Clin Oncol 2012; 42(4): 247-55.
87. Takayasu K, Arii S, Kudo M, et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol 2012; 56(4): 886-92.
88. Ikeda K, Kumada H, Saitoh S, et al. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model. Cancer 1991; 68 (10): 2150-4.
89. Mondazzi L, Bottelli R, Brambilla G, et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology. 1994; 19(5): 1115-23.
90. Golfieri R, Bilbao JI, Carpanese L, et al. Comparison of the survival and tolerability of radioembolization in elderly versus younger patients with unresectable hepatocellular carcinoma. J Hepatol. 2013; doi:10.1016/j.jhep.2013.05.025.
91. Nishikawa H, Osaki Y, Kita R, et al. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in Japan. Cancers 2012; 4: 165-83.
92. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
93. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
94. Kudo M, Tateishi R, Yamashita T, et al. Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system. Clin Drug Investig 2012; 32 Suppl 2: 37-51.
95. Kudo M, Ueshima K, Arizumi T. Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience. Dig Dis 2012; 30(6): 609-16.
96. Wong H, Tang YF, Yao TJ, et al. The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC). Oncologist. 2011; 16(12): 1721-8.
97. Di Costanzo GG, Tortora R, De Luca M, et al. Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma. Med Oncol. 2013; 30(1): 446.
98. Montella L, Addeo R, Cennamo G, et al. Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series. Oncology. 2013; 84(5): 265-72.
99. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-300.
100. Baek KK, Kim JH, Uhm JE, et al. Prognostic Factors in Patients with Advanced Hepatocellular Carcinoma treated with Sorafenib: A Retrospective Comparison with Previously Known Prognostic Models. Oncology 2011; 80: 167-74.
101. Llovet JM, Peña CE, Lathia CD, et al; on behalf of the SHARP Investigators Study Group: Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res 2012; 18: 2290-300.
102. Takeda H, Nishikawa H, Iguchi E, et al. Sorafenib-induced acute interstitial pneumonia in patients with advanced hepatocellular carcinoma: report of three cases. Clin J Gastroenterol 2012; 5: 407-12.
103. Takeda H, Nishikawa H, Iguchi E, et al. Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib. Mol and Clin Oncol 2013; 1: 241-48.
104. Nishikawa H, Osaki Y, Iguchi E, et al. Comparison of the efficacy of transcatheter arterialchemoembolization and sorafenib for advanced hepatocellular carcinoma. Exp Ther Med 2012; 4(3): 381-6.
105. Ikeda M, Mitsunaga S, Shimizu S, et al. Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. J Gastroenterol. 2013; [Epub ahead of print]
106. Morimoto M, Numata K, Kondo M, et al. Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatol Res. 2011; 41(4): 296-302.